Prostate Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Prostate Cancer, including details on symptoms, genetics, screening, treatment, information.

Volume 3 (2006), Issue 7 (July)

1. The E-cadherin -160 C/A polymorphism and prostate cancer risk in white and black American men.
   J Urol, 176(2): 793-6. [Abstract] [Full-text]
2. 25-year prostate cancer control and survival outcomes: a 40-year radical prostatectomy single institution series.
   J Urol, 176(2): 569-74. [Abstract] [Full-text]
3. Long-term outcome following radical prostatectomy in men with clinical stage T3 prostate cancer.
   J Urol, 176(2): 564-8. [Abstract] [Full-text]
4. Detectable prostate specific antigen between 60 and 120 days following radical prostatectomy for prostate cancer: natural history and prognostic significance.
   J Urol, 176(2): 559-63. [Abstract] [Full-text]
5. Pathological outcomes and biochemical progression in men with T1c prostate cancer undergoing radical prostatectomy with prostate specific antigen 2.6 to 4.0 vs 4.1 to 6.0 ng/ml.
   J Urol, 176(2): 554-8. [Abstract] [Full-text]
6. Locally advanced prostate cancer treated with concomitant radiation and 5-fluorouracil: Southwest Oncology Group Study 9024.
   J Urol, 176(2): 548-53; discussion 553. [Abstract] [Full-text]
7. Long-term followup of a randomized study of locally advanced prostate cancer treated with combined orchiectomy and external radiotherapy versus radiotherapy alone.
   J Urol, 176(2): 544-7. [Abstract] [Full-text]
8. Breast cancer as a second primary in patients with prostate cancer--estrogen treatment or association with family history of cancer?
   J Urol, 176(2): 538-43. [Abstract] [Full-text]
9. Intensity of androgen and epidermal growth factor receptor immunoreactivity in samples of radical prostatectomy as prognostic indicator: correlation with clinical data of long-term observations.
   J Urol, 176(2): 532-7. [Abstract] [Full-text]
10. Use of hormonal therapy in men with metastatic prostate cancer.
    J Urol, 176(2): 526-31. [Abstract] [Full-text]
11. The effect of androgen deprivation therapy on fasting serum lipid and glucose parameters.
    J Urol, 176(2): 520-5. [Abstract] [Full-text]
12. Black race does not independently predict adverse outcome following radical retropubic prostatectomy at a tertiary referral center.
    J Urol, 176(2): 515-9. [Abstract] [Full-text]
13. Continuing controversy over monitoring men with localized prostate cancer: a systematic review of programs in the prostate specific antigen era.
    J Urol, 176(2): 439-49. [Abstract] [Full-text]
14. NF-kappaB activation upregulates fibroblast growth factor 8 expression in prostate cancer cells.
    Prostate, 66(11): 1223-34. [Abstract] [Full-text]
15. New bone formation and osteolysis by a metastatic, highly invasive canine prostate carcinoma xenograft.
    Prostate, 66(11): 1213-22. [Abstract] [Full-text]
16. The North Carolina-Louisiana Prostate Cancer Project (PCaP): methods and design of a multidisciplinary population-based cohort study of racial differences in prostate cancer outcomes.
    Prostate, 66(11): 1162-76. [Abstract] [Full-text]
17. Expression of mTOR signaling pathway markers in prostate cancer progression.
    Prostate, 66(11): 1203-12. [Abstract] [Full-text]
18. Finasteride targets prostate vascularity by inducing apoptosis and inhibiting cell adhesion of benign and malignant prostate cells.
    Prostate, 66(11): 1194-202. [Abstract] [Full-text]
19. A histone deacetylation-dependent mechanism for transcriptional repression of the gap junction gene cx43 in prostate cancer cells.
    Prostate, 66(11): 1151-61. [Abstract] [Full-text]
20. Overexpression of EIF3S3 promotes cancer cell growth.
    Prostate, 66(11): 1144-50. [Abstract] [Full-text]
21. Genistein-induced neuroendocrine differentiation of prostate cancer cells.
    Prostate, 66(11): 1136-43. [Abstract] [Full-text]
22. Protein tyrosine phosphatase PTP1B is involved in neuroendocrine differentiation of prostate cancer.
    Prostate, 66(11): 1125-35. [Abstract] [Full-text]
23. Loss of Sef (similar expression to FGF) expression is associated with high grade and metastatic prostate cancer.
    Oncogene, 25(29): 4122-7. [Abstract] [Full-text]
24. High-grade and hormone-treated prostate cancer express high levels of thymidylate synthase.
    BJU Int, 98(1): 197-200. [Abstract] [Full-text]
25. Aberrant expression of cystatin C in prostate cancer is associated with neuroendocrine differentiation.
    BJU Int, 98(1): 189-96. [Abstract] [Full-text]
26. Assessment of aberrations on chromosome 8 in prostatic atrophy.
    BJU Int, 98(1): 184-8. [Abstract] [Full-text]
27. Pathological changes of high-grade prostatic intraepithelial neoplasia and prostate cancer after monotherapy with bicalutamide 150 mg.
    BJU Int, 98(1): 54-8. [Abstract] [Full-text]
28. Prostate specific-antigen distribution in asymptomatic Canadian men with no clinical evidence of prostate cancer.
    BJU Int, 98(1): 50-3. [Abstract] [Full-text]
29. Athermal Robotic Technique of prostatectomy in patients with large prostate glands (>75 g): technique and initial results.
    BJU Int, 98(1): 47-9. [Abstract] [Full-text]
30. Laparoscopic and robotic radical prostatectomy.
    Expert Rev Anticancer Ther, 6(7): 1003-11. [Abstract] [Full-text]
31. New molecular targets in advanced prostate cancer.
    Expert Rev Anticancer Ther, 6(7): 993-1002. [Abstract] [Full-text]
32. Clinical characteristics of bladder cancer in patients previously treated with radiation for prostate cancer.
    BJU Int, 98(1): 59-62. [Abstract] [Full-text]
33. Optimizing outcomes and quality of life in the hormonal treatment of prostate cancer.
    BJU Int, 98(1): 20-7. [Abstract] [Full-text]
34. Using prostate-specific antigen screening and nomograms to assess risk and predict outcomes in the management of prostate cancer.
    BJU Int, 98(1): 11-9. [Abstract] [Full-text]
35. Postoperative radiotherapy after radical prostatectomy for prostate carcinoma: the experience of the Brescia Radium Institute.
    Radiol Med (Torino), 111(5): 741-7. [Abstract] [Full-text]
36. Lifestyle intervention development study to improve physical function in older adults with cancer: outcomes from Project LEAD.
    J Clin Oncol, 24(21): 3465-73. [Abstract] [Full-text]
37. Aggressiveness of familial prostate cancer.
    J Clin Oncol, 24(21): 3445-50. [Abstract] [Full-text]
38. Identifying problems faced by spouses and partners of patients with prostate cancer.
    Oncol Nurs Forum, 33(4): 807-14. [Abstract] [Full-text]
39. Redistribution of androgen receptors in acquired hormone-refractory prostate cancer cells.
    Arch Androl, 52(5): 389-95. [Abstract] [Full-text]
40. Extraperitoneal laparoscopic radical prostatectomy.
    Arch Androl, 52(5): 383-7. [Abstract] [Full-text]

© 2004-2008 Prostate Cancer Research Today. All Rights Reserved.